Distinguished Technopreneur Speaker With Sir Gregory Winter

A*STAR Exploit Technologies is organising the 3rd Distinguished Technopreneur Speaker (DTS) Forum to seed innovation and entrepreneurship in Singapore. DTS aims to engage entrepreneurs, industry professionals, researches, scholars and students and inspire them to explore the potential of entrepreneurship, innovation and emerging technologies as envisioned by the new economy.

Sir Gregory Winter will be sharing with us the revolution in the pharmaceutical industry; small molecules drugs are being displaced by antibodies in the recent years. There are already six antibodies in the top 20 best-selling pharmaceutical drugs, and in 2014 it is predicted that there will be six antibodies in the top ten, with the first three slots occupied by antibodies. He will trace the technology that led to this revolution, and attempt to predict where the antibody revolution will go next, with the opportunities for science, medicine and commerce.

Speaker Profiles

SIR GREGORY WINTER

Sir Gregory Winter currently serves as the Deputy Director of the UK Medical Research Council (MRC) Laboratory of Molecular Biology, and is a Fellow of Trinity College in the University of Cambridge.

Amongst his many achievements, he pioneered a technique to “humanize” mouse monoclonal antibodies in 1986. The technique has since been licensed to around 50 companies, and led to the production of the blockbuster anti-cancer antibodies Herceptin and Avastin by Genentech.

In 1989 Sir Gregory Winter developed methods to make human antibodies directly, and founded Cambridge Antibody Technology. This led to the development of the blockbuster HUMIRA for treatment of rheumatoid arthritis, the first fully human monoclonal antibody drug. Subsequently Cambridge Antibody Technology was sold to AstraZeneca in 2006 (for £702 million).

Moderator Profile
PROFESSOR SIR DAVID LANE
CHIEF SCIENTIST, A*STAR AND CANCER RESEARCH UK

Professor Sir David Lane is the Chief Scientist of A*STAR, his main responsibility is to advise and engage in scientific development across the Biomedical Research Council (BMRC) and the Scientific Engineering Research Council (SERC) at the strategic level. He is also the Chief Scientist with the Cancer Research UK and the Director of the p53 Laboratory which focuses on research P53 using both mammalian and Zebrafish system.

He founded Cyclacel Pharmaceuticals Inc., a biotechnology company developing novel drugs for the treatment of cancer, with three oncology drug candidates in clinical trials.

Event Details

When: 19 January 2011 Wednesday
Time: 1:30 pm – 5:00 pm
Where: Exploration Theatrette, Level 4, Matrix Biopolis

Register before 3 January 2011, and stand a chance to win an early bird door gift. Limited to 150 early bird gifts to be given away. Registration will be closed on 10 January 2011.